Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Synflorix is a 10-valent pneumococcal conjugate vaccine (PHiD-CV) developed by GSK for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) caused by *Streptococcus pneumoniae* in infants and children. The vaccine contains capsular polysaccharides from 10 pneumococcal serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F). A unique feature of this vaccine is the use of a protein derived from non-typeable *Haemophilus influenzae* (NTHi), known as Protein D, as the carrier protein for eight of the ten serotypes, which may provide additional protection against NTHi-related otitis media. The remaining two serotypes are conjugated to tetanus toxoid and diphtheria toxoid. It is formulated with an aluminum phosphate adjuvant.
- Brand names
- Synflorix
- Other names
- 10-valent Streptococcus pneumoniae conjugate vaccine10-valent pneumococcal conjugate vaccine10PCV
02
Targets
PD (Protein D)TT (Tetanus toxoid)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed).